Please login to the form below

Not currently logged in
Email:
Password:

Editas Medicine adds to board of directors

Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins

Editas Medicine Dr Akshay VaishnawCambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors.

Dr Vaishnaw brings over 30 years of pharmaceuticals experience to the genome editing company, and currently serves as both executive vice president of research and development and chief medical officer at Alnylam Pharmaceuticals.

Prior to joining Alnylam in 2006, he worked in medical research at Biogen and held roles of increasing responsibility before becoming senior director of medical research.

Katrine Bosley, Editas Medicine's president and chief executive officer, said: “I am delighted to welcome Akshay to our board of directors.

“He has extensive clinical development experience, a passion for scientific excellence, and achieved significant accomplishments as part of the leadership team that has built Alnylam.

“We believe Akshay's perspective and advice will be invaluable as we continue to advance the organisation and drive innovative new medicines to treat genetic diseases.”

2nd August 2016

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Rich Quelch
Future-proofing pharma supply chains by improving inefficiencies in global health architecture
By Rich Quelch...
Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...